Literature DB >> 12771530

Hypertension and dialysis.

Matthias P Hörl1, Walter H Hörl.   

Abstract

The high mortality rate seen in dialysis patients is related to long-standing high blood pressure and the presence of other traditional as well as non-traditional risk factors for cardiovascular disease. Hypertension is associated with increased risk for left ventricular hypertrophy, coronary artery disease, congestive heart failure and cerebrovascular complications. High blood pressure is frequent and difficult to control in the dialysis population. Available therapeutic options to normalize blood pressure in these patients include dietary salt and fluid restriction in combination with reduction of dialysate sodium concentration. A possible treatment option for these patients may be long, slow hemodialysis (3 x 8 h per week); short daily hemodialysis (2-3 h 7 times per week); nocturnal hemodialysis (6-7 times overnight per week). Reduction of residual renal function is a major cause of blood pressure increase in the peritoneal dialysis patient population. Therefore, hyperhydration should be avoided. If antihypertensive medication is needed, ACE inhibitors, beta-blockers and/or calcium channel blockers are recommended. Optimal blood pressure in dialysis patients is not different from recommendations for the general population. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771530     DOI: 10.1159/000070987

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  2 in total

1.  Fluid balance assessment in pediatric hemodialysis patients by using whole-body bioimpedance spectroscopy (WB-BIS).

Authors:  Ei E Khin; Ayah Y Elmaghrabi; Luis A Alvarado; Vinai Modem; Raymond Quigley
Journal:  Pediatr Nephrol       Date:  2022-02-15       Impact factor: 3.651

2.  Escalating antihypertensive medications in end-stage renal disease patients does not improve blood pressure control.

Authors:  Mihály Tapolyai; Jariatul Karim; Atif Fakhruddin
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-03       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.